Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Established risk factors include: History of pancreatitis: Patients with prior episodes face substantially higher recurrence risk and require careful consideration before initiating GLP-1 therapy Gallstone disease: Cholelithiasis and biliary sludge can precipitate pancreatitis, particularly during periods of rapid weight loss Hypertriglyceridemia: Triglyceride levels 1,000 mg/dL significantly increase pancreatitis risk, with risk beginning to rise at levels 500 mg/dL Excessive alcohol consumption: Alcohol remains one of the most common pancreatitis triggers and may interact with metabolic changes induced by GLP-1 medications Obesity and rapid weight loss: While weight reduction is therapeutic, very rapid loss may increase gallstone formation Warning signs of acute pancreatitis that patients should recognize include severe, persistent abdominal pain, typically in the upper abdomen and often radiating to the back
Your provider will explain what the labs revealed and recommend appropriate next steps
The mechanism that slows gastric emptying, believed to cause gastroparesis, is present in both semaglutide and tirzepatide drugs
Seek specialty care when appropriate: Dermatologists and obesity medicine physicians are trained to individualize treatment safely
There is no medical contraindication to starting GLP-1 therapy on any particular day
Still, it cannot replace lost facial volume
